Last reviewed · How we verify
Pegylated interferon alpha 2
Pegylated interferon alpha 2 is a Interferon alpha Small molecule drug developed by Ain Shams University. It is currently FDA-approved for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).
Pegylated interferon alpha-2 activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity.
Pegylated interferon alpha-2 activates innate immune responses by binding to interferon-alpha receptors on immune cells, enhancing antiviral and antiproliferative activity. Used for Chronic hepatitis C, Chronic hepatitis B, Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas).
At a glance
| Generic name | Pegylated interferon alpha 2 |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Interferon alpha |
| Target | Interferon-alpha receptor (IFNAR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Virology, Oncology |
| Phase | FDA-approved |
Mechanism of action
Interferon alpha-2 is a cytokine that stimulates natural killer cells, macrophages, and T lymphocytes to mount antiviral and antitumor responses. Pegylation (attachment of polyethylene glycol) extends the drug's half-life and reduces immunogenicity, allowing for less frequent dosing while maintaining therapeutic efficacy. This modified form is used primarily in chronic viral infections and certain malignancies.
Approved indications
- Chronic hepatitis C
- Chronic hepatitis B
- Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)
Common side effects
- Flu-like symptoms (fever, chills, fatigue)
- Headache
- Myalgia
- Depression/mood changes
- Thrombocytopenia
- Neutropenia
- Anemia
- Injection site reactions
Key clinical trials
- A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B (PHASE2)
- Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) (PHASE2)
- Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection (PHASE2)
- Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PHASE3)
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE) (PHASE2)
- Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) (PHASE2)
- Pegasys® in Patients With Myeloproliferative Diseases (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pegylated interferon alpha 2 CI brief — competitive landscape report
- Pegylated interferon alpha 2 updates RSS · CI watch RSS
- Ain Shams University portfolio CI
Frequently asked questions about Pegylated interferon alpha 2
What is Pegylated interferon alpha 2?
How does Pegylated interferon alpha 2 work?
What is Pegylated interferon alpha 2 used for?
Who makes Pegylated interferon alpha 2?
What drug class is Pegylated interferon alpha 2 in?
What development phase is Pegylated interferon alpha 2 in?
What are the side effects of Pegylated interferon alpha 2?
What does Pegylated interferon alpha 2 target?
Related
- Drug class: All Interferon alpha drugs
- Target: All drugs targeting Interferon-alpha receptor (IFNAR)
- Manufacturer: Ain Shams University — full pipeline
- Therapeutic area: All drugs in Immunology, Virology, Oncology
- Indication: Drugs for Chronic hepatitis C
- Indication: Drugs for Chronic hepatitis B
- Indication: Drugs for Certain hematologic malignancies (e.g., chronic myeloid leukemia, lymphomas)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing